Clinical trials: Nutrition, open to volunteers
Obesity
Probiotic for Weight Management in Overweight and Obese Adults
To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and…
- Trial name
- NCT07507929
- Testing
- Probiotic
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Overweight, Obesity
Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin
The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.
- Trial name
- NCT07502001
- Testing
- Acetaminophen, Metformin, Warfarin
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Overweight and Obesity
A Study to Investigate the Safety and Efficacy of TE-8105 in Overweight or Obesity Participants
This is a Phase 2b, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of TE-8105 in adults with overweight or obesity…
- Trial name
- NCT07857473
- Testing
- TE-8105 MAD Cohort 1, TE-8105 MAD Cohort 2, TE-8105 MAD Cohort 3
- Where
- 2 sites in Australia
- Volunteers
- 204 people
- Sponsor
- Immunwork, Inc.
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Obesity, Overweight
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight.
- Trial name
- NCT07684235
- Testing
- Maridebart cafraglutide
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 3,200 people
- Sponsor
- Amgen
Obesity
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause.
- Trial name
- NCT07850050
- Testing
- Survodutide
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Boehringer Ingelheim
Obesity
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 1 (NCT07339423)
- Testing
- NNC0487-0111
- Where
- 72 sites in United States, Argentina and 7 more
- Volunteers
- 1,150 people
- Sponsor
- Novo Nordisk A/S
Obesity, Heart Failure
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body…
- Trial name
- HF-POLARIS (NCT07567001)
- Testing
- NNC0487-0111
- Where
- 838 sites in United States, Argentina and 25 more
- Volunteers
- 5,610 people
- Sponsor
- Novo Nordisk A/S
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
End Stage Renal Disease (ESRD)
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
This is a multicenter, randomized, parallel controlled Phase IV clinical study to evaluate the safety and efficacy of amino acid (15) peritoneal dialysis solution in patients undergoing peritoneal dialysis with malnutrition in…
- Trial name
- NCT06597201
- Testing
- amino acid (15) peritoneal dialysis solution, glucose peritoneal dialysis solution
- Where
- 21 sites in China
- Volunteers
- 400 people
- Sponsor
- Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Obesity or Overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith1 (NCT07351045)
- Testing
- Enicepatide
- Where
- 209 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Eosinophilic Esophagitis (EoE)
Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut…
- Trial name
- NCT07234825
- Testing
- Partial enteral nutrition (PEN) with dairy elimination, Dairy elimination alone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kate Farms Inc
Obesity, Overweight
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure.
- Conditions
- Obesity, Overweight, Obstructive Sleep Apnoea
- Trial name
- AMAZE 4 (NCT07571109)
- Testing
- NNC0487-0111
- Where
- 92 sites in United States, Australia and 8 more
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Prader-Willi Syndrome
A Study of Pitolisant in Patients With Prader-Willi Syndrome
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome.
- Trial name
- NCT06366464
- Testing
- Pitolisant tablet
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 134 people
- Sponsor
- Harmony Biosciences Management, Inc.
Obesity / Overweight
A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.
This is a placebo-controlled, double-blind trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of TQF6422 Injection in overweight or obese healthy participants.
- Trial name
- NCT07794111
- Testing
- TQF6422 Injection
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Healthy Participants
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
- Trial name
- NCT07723833
- Testing
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Drug Drug Interaction (DDI), Pharmacokinetics and Pharmacodynamics
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
This is a Phase I, open-label, two-cohort study designed to evaluate the drug-drug interaction potential of multiple-dose UBT251 Injection in adult participants with overweight or obesity.
- Trial name
- NCT07785934
- Testing
- UBT251, Metformin hydrochloride, Warfarin Sodium
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Malnutrition (Calorie)
Stunting and Targeting Reduction of Impaired Growth in Kids Effectively
The objective of this prospective, real-world evidence/pragmatic study with a quality improvement program approach is to evaluate the feasibility and effectiveness of a community-engaged nutrition-focused program utilizing…
- Trial name
- STRIKE (NCT07524907)
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Abbott Nutrition
Overweight , Obesity
Study of UBT37034 Injection
This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated…
- Trial name
- NCT07873645
- Testing
- UBT37034
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.